Skip to main content

Table 3 Quality assessment results of evidence used based on the hierarchy of data sources by Cooper et al. [12]

From: Pharmacogenetic testing for adverse drug reaction prevention: systematic review of economic evaluations and the appraisal of quality matters for clinical practice and implementation

Input parameters Hierarchy of data sources % Agreement*
1 2 3 4 5 6 9 #
Clinical effect sizes 16 (27%) 0 0 29 (49%) 0 2 (3%) 4 (7%) 8 (14%) 85
Baseline clinical data 4 (7%) 1 (2%) 0 51 (85%) 1 (2%) 1 (2%) 1 (2%)   81
Resource use 7 (12%) 51 (86%) 0 0 0 1 (2%) 0   92
Costs 6(10%) 53 (90%) 0 0 0 0 0   85
Utility 2(5%) 0 38 (93%) 1 (2%) 0 0 0   97
  1. # Meta-analysis of case-control with direct comparison between comparator therapies and measuring final outcomes
  2. *Percentage of agreement between two independent raters